These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11342323)

  • 21. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy.
    Castagnola E; Dallorso S; Faraci M; Morreale G; Di Martino D; Cristina E; Scarso L; Lanino E
    J Hematother Stem Cell Res; 2003 Feb; 12(1):9-10. PubMed ID: 12662431
    [No Abstract]   [Full Text] [Related]  

  • 22. Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab.
    Courby S; Fabre B; Salameire D; Gaulard P; Hincky-Vitrat V; Gressin R; Bonaz B; Epaulard O
    Leuk Lymphoma; 2010 Jan; 51(1):174-7. PubMed ID: 20001240
    [No Abstract]   [Full Text] [Related]  

  • 23. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
    González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
    Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment with rituximab of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.
    Jericho H; Weinstein J; Melin-Aldana H; Leuer KC; Wyers M; Alonso EM; Ekong UD
    J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):e2-4. PubMed ID: 24378523
    [No Abstract]   [Full Text] [Related]  

  • 25. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab.
    Iu LP; Yeung JC; Loong F; Chiang AK
    Pediatr Blood Cancer; 2015 Jan; 62(1):169-72. PubMed ID: 25174958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
    Banks CA; Meier JD; Stallworth CR; White DR
    Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
    Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
    Choquet S; Leblond V; Herbrecht R; Socié G; Stoppa AM; Vandenberghe P; Fischer A; Morschhauser F; Salles G; Feremans W; Vilmer E; Peraldi MN; Lang P; Lebranchu Y; Oksenhendler E; Garnier JL; Lamy T; Jaccard A; Ferrant A; Offner F; Hermine O; Moreau A; Fafi-Kremer S; Morand P; Chatenoud L; Berriot-Varoqueaux N; Bergougnoux L; Milpied N
    Blood; 2006 Apr; 107(8):3053-7. PubMed ID: 16254143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
    Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
    Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
    Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
    Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus-related lymphoproliferative disorders.
    Wagner-Johnston ND; Ambinder RF
    Curr Hematol Malig Rep; 2007 Oct; 2(4):249-54. PubMed ID: 20425377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).
    Oertel SH; Verschuuren E; Reinke P; Zeidler K; Papp-Váry M; Babel N; Trappe RU; Jonas S; Hummel M; Anagnostopoulos I; Dörken B; Riess HB
    Am J Transplant; 2005 Dec; 5(12):2901-6. PubMed ID: 16303003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.
    Ghobrial IM; Habermann TM; Ristow KM; Ansell SM; Macon W; Geyer SM; McGregor CG
    Leuk Lymphoma; 2005 Feb; 46(2):191-6. PubMed ID: 15621801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
    Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
    J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma.
    Ohta M; Taga T; Nomura A; Kato H; Takano T; Maruo Y; Takeuchi Y; Ishida M; Ohta S
    J Med Virol; 2011 Sep; 83(9):1582-4. PubMed ID: 21739449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.